Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease
Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease
复制标题
DOI：
10.3233/jad-2009-1075
复制
发表时间：
2009-07-01
影响因子：
4
通讯作者：
Otto, Markus
中科院分区：
文献类型：
--
作者：
Jesse, Sarah;Steinacker, Petra;Otto, Markus
胶质细胞酸性蛋白（GFAP）和蛋白S-100 B是神经病理学中星形胶质细胞增生的既定指标。由于GFAP和S-100 B在不同的细胞群中表达，这些蛋白质的可变脑脊液（CSF）浓度可能反映疾病特异性病理特征。因此，我们研究了阿尔茨海默病（AD）患者、克雅氏病（CJD）患者和非痴呆对照患者（CON）的CSF。CSF中GFAP和S-100 B的测量通过市售ELISA进行。我们的研究结果表明，在AD中，与CON（p = 0.001）和CJD患者（p = 0.009）相比，GFAP浓度水平显著更高，而与AD（p = 0.001）和CON（p = 0.001）相比，CJD中的S-100 B要高得多。总之，GFAP和S-100 B代表星形胶质细胞标志物，这些蛋白在AD和CJD患者CSF中的不同水平可能指向这些疾病的不同病理生理参与。除了病理生理学方面之外，GFAP特别地可以用作AD的另外的诊断工具，这是由于该蛋白质与已建立的标记物如tau和淀粉样蛋白-β不相关的事实，使得GFAP的分析可以用于神经变性疾病中的进一步鉴别诊断方法。
Glial fibrillary acidic protein (GFAP) and protein S-100B are established indicators of astrogliosis in neuropathology. As GFAP and S-100B are expressed in different cell populations, variable cerebrospinal fluid (CSF) concentrations of these proteins might reflect disease-specific pathological profiles. Therefore we investigated CSF of patients with Alzheimer's disease ( AD), patients with Creutzfeldt-Jakob disease (CJD), and non-demented control patients ( CON). Measurement of GFAP and S-100B in CSF was performed by commercially available ELISA. Our results show that, in AD, there are significantly higher levels of GFAP concentrations, compared to CON (p = 0.001) and CJD patients ( p = 0.009), whereas S-100B is much higher in CJD, compared to AD (p = 0.001) and CON (p = 0.001). In conclusion, GFAP and S-100B represent astroglial markers and the different levels of these proteins in CSF of AD and CJD patients might point to a distinct pathophysiological involvement in these diseases. Apart from pathophysiological aspects, GFAP in particular might serve as an additional diagnostic tool for AD, due to the fact that this protein does not correlate to established markers like tau and amyloid-beta such that analysis of GFAP may be useful for further differential diagnostic approaches in neurodegenerative diseases.